We are pleased to announce that AcariaHealth has been selected by Ipsen as a limited distribution partner to dispense IQIRVO® (elafibranor) 80 mg tablets. IQIRVO received accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.

According to the National Institute of Health, primary biliary cholangitis is a chronic disease in which the small bile ducts in the liver become injured and inflamed until they are eventually destroyed. Due to the lack of bile ducts, bile builds up and causes liver damage. Although many people have no symptoms when they are first diagnosed, early symptoms can include fatigue and itchy skin. The cause of PBC is unknown.

As a trusted healthcare partner, AcariaHealth remains dedicated transforming lives with compassionate care by ensuring timely medication delivery, ongoing assistance, and superior patient care. Patients and healthcare providers can rely on AcariaHealth for quality service and support throughout their treatment journey.

Download the referral form.

For more information about IQIRVO, please see the IQIRVO Full Prescribing Information. Additional information for patients and physicians can also be found at ipsencares.com/iqirvo-patient-support.

Catch the latest news and updates from AcariaHealth! Follow us on LinkedIn to stay informed about important announcements and industry insights.